SCHEMBL5201738

SCHEMBL5201738

CCOC(C)=NC(=O)c1cc(OC)cc(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.50
ALDH1A1 P00352 1/20 0.49
NPC1 O15118 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
PKM P14618 1/20 0.43
CYP3A4 P08684 1/20 0.42
HPGD P15428 1/20 0.42
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
POLB P06746 1/20 0.39
SIRT3 Q9NTG7 1/20 0.39
BRAF P15056 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5206335 1.00 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1NPC1MAPK1HTT
SCHEMBL5203413 0.85 NPC1 (0.53) SMN1; SMN2ALDH1A1NPC1MAPK1KMT2A
SCHEMBL5203419 0.85 NPC1 (0.53) SMN1; SMN2ALDH1A1NPC1MAPK1KMT2A
SCHEMBL5202714 0.84 HDAC3 (0.50) ALDH1A1NPC1HTTKMT2AKDM4E
SCHEMBL5202719 0.84 HDAC3 (0.50) ALDH1A1NPC1HTTKMT2AKDM4E
SCHEMBL5205744 0.77 MAPK1 (0.52) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL5205736 0.77 MAPK1 (0.52) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL3258075 0.75 MEN1 (0.64) SMN1; SMN2ALDH1A1NPC1MAPK1HTT
SCHEMBL515715 0.75 MEN1 (0.47) SMN1; SMN2ALDH1A1NPC1KMT2AMEN1
SCHEMBL5205967 0.75 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1NPC1MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458706-B1 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ CORP (KR) 2007-07-11 EP disclosed
US-7169929-B2 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP. (KR) 2007-01-30 US disclosed
US-7135572-B2 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP (KR) 2006-11-14 US disclosed
US-20060009495-A1 Diary 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP. (KR) 2006-01-12 US disclosed
EP-1458706-A4 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ CORP (KR) 2005-06-08 EP disclosed
US-20050075373-A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP. (KR) 2005-04-07 US disclosed
EP-1458706-A1 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ Corp. (KR) 2004-09-22 EP disclosed
WO-2003055875-A1 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ CORP. (KR) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009495-A1 Diary 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor PTGS1, PTGS2, PTGES2 SMN1; SMN2 4607/4885ALDH1A1 110/4885NPC1 4852/4885
US-20050075373-A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor PTGS1, PTGS2, PTGES2 SMN1; SMN2 4701/4885ALDH1A1 120/4885NPC1 4850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.